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A typical microarray experiment requires both a biochip on which the biological reactions take place and
a microarray scanner for analysis and visualization of the data. Here, we report on the generation of a
chip, which consists of a CMOS photodiode array onto which receptors are immobilized and which are
used for the detection and quantification of proteins in sera solution. Such an approach allows direct
electronic read-out of the chip via a computer port so that the size of the whole analytical setup is very
compact, opening the avenue to the generation of simple handheld devices. ELISA reactions directly
performed on the surface of the photodiode arrays are used to measure a number of serum factors with
a broad range in concentrations of samples with volumes of less than 10 ll. As in physiological sera
analyte concentrations of the different parameters vary frequently by several orders of magnitude,
parallel competitive reactions are used to adjust the dynamic range of several ELISA tests on the chip.
We show as a demonstration case that this allows to quantify simultaneously C-reactive protein,
Immunoglobulin E, Cystatin C, Myoglobin and Ferritin in a single assay.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recently much effort has been spent in the area of microarrays
to bring this technology into non-research markets [6,25]. One of
the drivers for technology is the demand for point-of-care diagnos-
tics (POC) [18]. Several attempts have been made to minimize the
size of microarray peripherals (e.g. fluorescence scanners) and to
reduce the analysis times [4,10,14,21]. One of these approaches
is to perform multiple analyses directly on a silicon sensor array,
where both biological and electronic detection are integrated in
one device. A number of detection systems have been proposed
and described, such as ISFETs to measure changes in electric charge
[3,13,16,22] or chemical electrodes for the measurement of redox
reactions [5,7,26]. While other research efforts on electronic
read-out of biochips were placed on the analysis of nucleic acids
[24], we published an approach, where we immobilized antibodies
on a CMOS photodiode sensor array to perform multiple sandwich-
ELISA‘s (sandwich enzyme-linked immunosorbent assays) on the
surface of one chip [1,9]) (Fig. 1). Sandwich-ELISA reactions havethe advantage, that it is not required that the analyte proteins must
be labeled prior to analysis and that the receptor bound to surface
can be a structurally rather simple compound, which enhances the
robustness of the process [19,20]. Accordingly, sandwich ELISA
are a standard technique in a number of POC applications such
as lateral flow devices (LFD) or dipsticks [2,11,12]. Here, we chose
a panel of assays that are regularly performed in the clinical
laboratory to have access to well characterized samples. To
demonstrate the technology several well established, clinically
important blood factors were chosen: C-reactive protein (CRP),
Cystatin C (CyC), Immunoglobulin E (IgE), Myoglobin and Ferritin.
One of the main problems of any multi-analyte approach is the
limited dynamic range of the ELISA reactions [17]. The concentra-
tions of relevant clinical blood factors vary in a range of about six
orders of magnitude, which exceeds the dynamic range of typical
ELISA tests by far [15]. Therefore, either several chips must be used,
where each of them contains only assays of the same dynamic
range, or methods must be applied so that a single analysis can
be performed in the desired range. Here, we study in how far the
addition of competitive mono- and bi-valent fragments of
analyte-specific antibodies to the sample volume can be used to
shift the concentration range of the analyte proteins in such a
way that always the highest sensor sensitivity is achieved.
Fig. 1. Schematic drawing of the measurement principle used by the CMOS-chips. Blood serum proteins are analyzed by a sandwich ELISA. The signal is generated by
horseradish peroxidase (HRP) attached via streptavidin to the detection antibody. The enzyme oxidizes luminol to generate light that is detected by the CMOS photodiode.
Table 1
List of antibodies used in the study.
Capture antibodies* Supplier and trade name
CRP antibody (AK03) Acris 4C28-C6
CRP antibody (AK04) Acris 4C28-C7
CyC antibody (AK02) Acris DP2003
Fe antibody (AK01) Acris AB9236
Fe antibody (AK06) Biodesign MCM04-175
GFP antibody (AK02) Acris R1091P
My antibody (AK15 Biodesign K31015G
IgE antibody (AK19) Phadia mAb 354
IgE antibody (AK20) Phadia mAb 351
Detection antibodies Supplier and trade name
GFP antibody Acris R1461P
CRP antibody Acris 4C28-C6
CyC antibody Acris DP2003
Fe antibody Biodesign MCM04-175
My antibody Biodesign K31015G
IgE antibody Chemicon AP175
* CRP: C-reactive protein, CyC: Cystatin C, Fe: Ferritin, GFP: green fluorescence
protein, IgE: Immunoglobulin E, My: Myoglobin.
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2.1. Chip generation
For the read-out of the chips a chemiluminescence reaction was
used, whose intensity was recorded by a semiconductor device
which has been described by Baader et al. [1]. Briefly, the device
consists of 32 photo sensors in an active pixel configuration [8],
which were arranged in a 4  8-array. The chip was fabricated in
a standard mixed signal 0.5 lm CMOS technology process by
Micronas GmbH, Freiburg, Germany. Each pixel consisted of a Ø
190 lm silicon photodiode and an integrated active amplifier
which can be addressed individually. The n-well/p-substrate
photodiode was operated in reverse bias and the photocurrent iph
plus a thermally induced ‘‘dark current” idark were integrated in
the p–n junction’s capacitance Cpn (Eq. (1)). For all experiments
performed the amplification A of the integrated amplifier was set
to 10.
dudiodeðtÞ
dt
¼ A iph þ idark
Cpn
ð1Þ
The cavities within the photodiodes each had a depth of 3 lm.
The diodes were covered with thermally grown silicon dioxide
with a thickness of about 300 nm. The almost circular photodiodes
had a diameter of 190 lm with a pitch of 500 lm (center to cen-
ter). The sensor array was packaged in a commercially available
photolithographically structured analysis cell (microTEC Ges. for
Microtechnology mbH, Duisburg, Germany). The analysis cell had
a volume of 40 ll. The semiconductor chip was wire bonded onto
a ceramic substrate to fit a standard socket.
To improve protein binding the diodes were coated with thin
layers of glycidoxypropyl trimethoxysilane. 2–10 nm thick silane
layers were deposited by dip coating and subsequently crosslinked
by heating in air for 1 h to 80 C to form very stable surface
attached thin silane layers on the chip surfaces[9].2.2. Probe Immobilization
The semiconductor microarrays were cleaned using compressed
nitrogen to remove loosely adhering dust particles. The chips were
then arranged in a custom made 56 chip holder and placed in a
SciflexTM S5 printer (Scienion AG, Berlin, Germany). Then the head
camera of the printer was placed over the photodiodes to inspect
all chips. Chips with remaining particles or other visible flaws were
discarded. Following inspection of the photodiodes the printer
software scanned all arrays and the control software stored the
position of each photodiode. Then the print plate (a 384-well
microtiter plate) was inserted into the printer and the printing
process started. All print media were 3.3 lM antibody solution in
sterile filtered 20 mM PBS solution. The antibodies used in the
study are listed in Table 1.
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each medium was printed in triplicates with approx 2.4 nl of liquid
spotted on each photodiode to ensure that the whole 190 lm
diameter sensor field was covered. After printing each medium
the nozzle was emptied and ultrasonicated in distilled water. Then
new medium was taken from the microtiter plate and printed.
Before starting the printing process the print nozzle was placed
in front of the camera and inspected for spot size and to ensure
that the drop trajectory was straight. Only when spots were
printed correctly the printing was started. After printing all the
media the chips were inspected for successful printing. If any
diodes were not fully covered with antibody solution a manual
repair print was started. Afterwards all chips were photographed
for quality control. Finally, the chips were stored in polypropylene
bags (PP-bags) under nitrogen atmosphere at 4 C. To avoid
condensation, drying bags were added into the PP-bags prior to
sealing.
2.3. Assay performance
All assays were performed using a wash buffer (20% (w/w) SSC,
0.1% (w/w) SDS, 0.05% (v/v) Tween20). Unbound antibodies were
removed from the chip by rinsing the chips in a washing buffer
(3 times/5 min) and 10 mM PBS-buffer prior to serum incubation.
Afterwards chips were dried using a folded soft paper and 40 ll
of the serum in the appropriate dilution were applied (all serum
dilutions in PBS-T-BSA). Serum incubation took place at room
temperature for 1 h. Chips were then again washed with wash
buffer (3 times/5 min), rinsed with PBS-buffer and the biotin
labeled secondary antibodies were applied (10 lg/ml) for 15 min.
Unbound antibodies were removed by a further wash step and
streptavidin-HRP was applied for 1 h (1:500 dilution in PBS-T-
BSA). After a fourth washing step the chips were loaded with
PBS-T-BSA-buffer and measured in a lightproof box to record the
dark current level. Finally, the PBS-T-BSA was exchanged to
enhanced chemiluminescence solution (ECL – Amersham ECl
Western Blotting Detection Reagent RPN2106) solution (prepared
according to the manufacturers instruction) and the HRP generated
chemiluminescence was recorded.
2.4. Data analysis
The recorded data were analyzed by calculating the slope of the
capacitance discharge of the photodiode over time using data
points between 110 and 500 ms. All data were then normalized
by the green fluorescent protein (GFP) value from the same exper-
iments, allowing to compare measurements made at different days
or with varying parameters. GFP was used as an internal control
and was spiked to the serum dilution in a concentration of
0.1 lg/ml. For the purpose of calibration, a range of sera with dif-
ferent concentrations within the relevant range were produced.
This was done by mixing the sera with high and low concentra-
tions of the different parameters to produce well distributed data
points in the dynamic range of the assay. These sera were then
used to calibrate a new batch of chips. Using these calibration data
a 4-parametric logistic curve was fitted through the data points.0
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Fig. 2. Voltage signal of the photodiode as a function of time, ( ) blank
measurement; PBS solution ( ) 15 mg/ml CPR in PBS ( ) difference signal;
measurements were performed on the same photodiode.3. Results
3.1. Measurement principle
Sandwich-ELISA assays were performed on the chips with
biotin conjugated secondary (detection) antibodies. The biotin
was used in a further step to attach streptavidin-conjugated HRP
or streptavidin-Cy5. The latter is used if fluorescence detection ispreferred. In the case of chemiluminescence detection peroxide
generated by the HRP oxidized luminol with the emission of light
was used and the luminescence signal was directly measured on
the chip by the photodiodes as described in detail in Baader et al.
[1]. The change of the voltage with time of each photodiode was
measured over a period of 1 s and recorded on a personal computer
with a sampling rate of 100 Hz. The emission of chemilumines-
cence leads to slower decay of the potential with time and accord-
ingly the slope of the voltage vs. times curves is directly
proportional to the light emission and thus the number of detec-
tion antibodies. Examplarily, data for one photodiode are shown
in Fig. 2.
To determine the dark current a measurement was performed
where the solution contained only buffer. Then the buffer was
exchanged by ECL solution and the diode current was immediately
recorded. No cross-talk between photodiodes has been observed.
For analysis the dark current was subtracted from the ECL signal.
For control measurements chips were stained with streptavidin-
Cy5 and measured in a microarray scanner. Furthermore, a chip
internal reference was added to the panel: an antibody against
green fluorescent protein (GFP) was incorporated into the assay.
GFPwas chosen because it does not naturally occur in human blood.
3.2. Immobilization of the antibodies
A chip assembly was designed consisting of the silicon sensor
array with 32 photodiodes and an integrated flow cell (Fig. 3).
The SiO2 passivation layer on the photo diode surface was
activated prior to printing through application of thin networks
of an expoxy-silane (i.e. glycidoxypropyl trimethoxysilane) [23].
The glycidyl group of the silane reacts with amino groups of the
biomolecules, which become this way covalently bonded to the
chip surface. These silane network layers bind more biomolecules
and exhibit a stronger chemical resistance against adverse
environmental conditions than the commonly used self-assembled
monolayers [23].
For two antibodies the binding capacity of the surface was ana-
lyzed by printing Dy647-labeled antibody on the surface. Initially
the label density of these antibodies was measured in solution by
photometry in order to define the label ratio of the protein. The
label density was determined to be 3 fluorophores per protein
molecule. These labeled antibodies were then mixed with unla-
beled antibodies to avoid quenching of the fluorophores. The mix-
ture was then printed on the photodiodes and the fluorescence
intensity of the spots was measured in a Biodetect100 biochip
scanner. Then the chips were washed to remove unbound protein
and were measured again. Relative fluorescence of each spot was
analyzed with the Signalyse (Klapproth und Rühe GbR, Freiburg)
software and compared to the signal prior to washing. The mea-
sured antibody binding was 5140 antibodies/lm2.
Fig. 3. (a) Photograph of the semiconductor chip packaged with a flow cell on a ceramics substrate. (b) Magnification of the photodiode array (scale bar represents 500 lm).
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A panel of 10 capture antibodies was chosen to demonstrate the
performance of the chip. These antibodies can detect 5 different
blood parameters and one calibration standard. Two of these fac-
tors have diagnostic decision values in the lg/ml-range (CRP and
CyC), another two factors (Myoglobin and Ferritin) have decision
values in the range of ng/ml whereas the fifth parameter (IgE) lies
in between these ranges. For CyC and the calibration standard GFP
only one capture antibody was printed whereas for the other
parameters two different capture antibodies were immobilized.
Each of the antibodies was printed in triplicate on the array. Assays
were performed with a standard ELISA protocol where the
secondary (detection) antibody was biotin conjugated. For the
detection reaction streptavidin conjugated HRP was used together
with ECL solution [1]. Some chips were also measured with
streptavidin-Cy5 to compare electrical measurements with
fluorescence data.
3.4. Biosensor characterization
All antibody pairs were tested with reference serum mixtures
obtained from human donors to produce a calibration curve. These
sera were analyzed by a clinical laboratory applying gold standard
measurements (immunenephelometry/immunoturbidimetry). All
sensor chip calibrations were performed with human sera samples
to be able to compare the responses of the chip to reference data.
Three of the chosen assays (IgE, Myoglobin and Ferritin) produced
calibration curves where the clinically relevant concentrations
were within the dynamic range (Fig. 4a–c). The two assays for
CyC (data not shown) and CRP (Fig. 4e) already reached saturation
at lower concentrations than the relevant levels. The levels of
saturation were in the range of 10–100 ng/ml, which are much
lower than the clinical decision values which are in the range of
1–5 lg/ml.
3.5. Customization of the dynamic range
For assays where the clinical decision values were above the
saturation level, experiments were performed to shift the dynamic
range of the assay into the desired signal range. In a first set of
experiments well defined amounts of capture antibody were added
to the sample to bind a certain fraction of the analyte and therefore
reduce the free amount of analyte that can bind to immobilized
capture antibodies. With this strategy we were able to shift
the dynamic range of the CyC assay to the relevant value of
1.2 lg/ml (Fig. 4d). The modified assay had a range from below
0.5 ng/ml to up to 4 lg/ml. The lower limit of detection might be
even lower, but no serum with less than 0.5 ng/ml was available
to us. While this approach was successful for CyC, in the case ofCRP the dynamic range of the assay decreased from 3 decades to
less than 1 decade making that method unsuitable (data not
shown). Therefore, a different approach was investigated. Instead
of using whole antibodies the binding site competition was per-
formed with F(ab) fragments to avoid immunoprecipitation. This
method allowed shifting the concentration response curve of the
assay into the desired range without compromising on the
dynamic range. Different amounts of F(ab) fragments added to
the serum prior to incubation gave concentration dependent shifts
in the response curve. By adding 2.5 lg/ml CRP ab1 F(ab) frag-
ments the assays could be centered around the critical value of
3 lg/ml (Fig. 4f). With these changes the dynamic range is from
below 0.5 lg/ml to 10 lg/ml for CRP ab2. CRP ab1 the capture anti-
body used to produce the F(ab) fragments, still had a reduced
dynamic range, but it was well centered around the decision value.
It could be used for measurements in that range.
3.6. Gold standard comparison
To check the accuracy of the described microarray, test analyses
was performed using 12 ll of an unknown serum sample to pro-
duce 120 ll of 1:10 diluted serum. An assay was performed on
three chips and compared to a calibration curve recorded with
chips from the same production batch. For calibration, analyzed
human sera samples were used. In parallel the unknown serum
sample was analyzed at two different reference laboratories (at
the department of clinical chemistry of the University Hospital
Freiburg and Labor Clotten, Freiburg) using classical clinical chem-
istry. The data were afterwards compared to see if the microchip
data matched the data recorded by using standard methods. As
seen in Table 2 the data matched well, especially when the scatter-
ing of the results, where gold standard procedures have been fol-
lowed in different laboratories to analyze the same sample. The
microchip data obtained by mixing of known sera showed a very
good correllation with clinical laboratory results in the case of
CyC, IgE, spiked CRP and Ferritin (r2 > 0.99 and a slightly weaker
r2 of 0.947 for Myoglobin. Unspiked CRP was not used in the
analysis but had a r2 of 0.986.4. Discussion
The analyses performed here show that multiplex sandwich-
ELISA type experiments can be performed on semiconductor chips
having a comparable range to classical ELISA experiments. For
some of the physiological parameters the problem was that the
relevant clinical decision values were far above the upper limit of
detection. In standard solution based ELISA tests this is done with
multiple dilution series. On a microarray this option is not feasible.
Therefore, the assays were adjusted to work with one single serum
dilution by adding small, controlled amounts of an antibody to the
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Fig. 4. Calibration curves for the ELISA reactions used in the assay; dashed lines indicate the clinical decision values. (a) IGE assays reached their saturation well above
1000 IU/ml (1 IU = 1 ng/ml) and the clinical decision values are well in the dynamic range. (b) For Ferritin there were two clinical decision values, an upper and a lower limit.
The dynamic range of the assay allowed the detection of both. (c) The assay for Myoglobin was also well centered around the clinical decision value. (d) For Ferritin the assay
clinical decision value was already in the dynamic range, between upper and lower limit of detection. (e) CRP assay signals reached saturation in the ng/ll range, far below
levels relevant for clinical diagnostics (f). Adding anti-CRP-Fab fragments in small amounts to the analyte decreased the amount of available analyte and shifted the assay into
the desired lower lg/ml range. Two different antibody pairs were used in both assays. Measuring points indicate average values of three chips with each antibody printed in
triplicates (error bars show s.e.m.). (f) In the case of Cystatin C the assay was shifted by the addition of whole anti-CyC antibody to reach the required values.
Table 2
Analyte concentrations in one human serum sample determined by the Micronas
biochip and two clinical reference laboratories.
Parameter Dimension Reference
lab 1
Reference
lab 2
Biochip
results
Clinical
decision
value
CRP lg/ml 3.5 2.9 2.7 5
CyC lg/ml 1.01 1.33 1.1 1.2
IgE IU/ml 36 58 50 100
Fe ng/ml 35.8 53 45 15–400
My ng/ml 50 77 85 90
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tain fraction of the analyte. While for the majority of parameters
this approach proved to be simple and successful, interestingly
the most problematic ELISA test to adapt was CRP – which is a
homopentameric protein. Obviously adding a ‘‘normal” antibodyto a CRP containing solution leads to strong aggregation of CRP
and its antibody, so that the measurement is impaired. Splitting
the bivalent antibody into monovalent Fab fragments solved this
problem. This deactivation strategy allows now to measure ana-
lytes with strongly differing concentration ranges on one single
chip. The semiconductor microarray has proven to be a useful tool
for rapid blood serum analysis, as shown by analyzing a group of
serum proteins with greatly differing concentration ranges. The
correlation of the measured values to the data from reference lab-
oratories demonstrates the validity of the measured data. While
some problems, such as packaging and assay optimization still
have to be solved for point-of-care analysis, the data shows the fea-
sibility of the electronic sensors for this type of application. One
feature we are currently working on to improve is the time to
result of the analysis process. Including the wash steps, which have
been adapted from ELISA plate tests, the assay still takes at least
one hour. Several options are available to resolve this problem.
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detection enzyme HRP to the detection antibody, thereby reducing
the assay by one washing and one incubation step. Secondly, the
analyte binding step and the conjugate binding step could be
performed simultaneously on the chip to save even more time.
To develop this as a point-of-care system will require a peripheral
system for serum generation and for fluid transport. As integrated
serum generation is already used in systems such as LFDs, this
requirement seem to be not too stringent for the performance of
CMOS protein microarray recordings. This would enable general
practitioners to perform highly sensitive measurements while
their patients are waiting.
5. Conclusions
The described integrated sensor and detector platform which
uses for biochip read-out a standard CMOS based photodiode arrays
combined with an on-chip ELISA allows the parallel detection of
various blood serum parameters with largely varying concentration
ranges. A special emphasis was put on the possibility to manufac-
ture this device in standard semiconductor chip production lines
to be able to mass manufacture with the cost and quality of modern
electronic chip production standards. Additionally, the CMOS based
chip requires no image analysis steps with all the possible pitfalls
which are common for typical fluorescence based biochip read-
out devices. As not only the biological detection system is
miniaturized, but also the electronical read-out system, this allows
to integrate the system including peripherals and data transmission
into a rather small and portable device.
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